ArticleChembiochem : a European journal of chemical biology2008
Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Article in Chembiochem : a European journal of chemical biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.Journal for immunotherapy of cancer · 2020Trial
- A lyophilizable LNP vaccine enables STING-reinforced postoperational adjuvant immunotherapy.Journal of nanobiotechnology · 2025Article
- Immunological and Toxicological Assessment of Triterpenoid Saponins Bearing Lewis-X- and QS-21-Based Trisaccharides.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- B-1 B Cell-Derived Natural Antibodies against N-Acetyl-d-Glucosamine Suppress Autoimmune Diabetes Pathogenesis.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models.Vaccines · 2023Article
- Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.Pharmaceutics · 2022Article
- Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae.Advanced materials (Deerfield Beach, Fla.) · 2022Article
- Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin.Frontiers in immunology · 2021Article
- Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment.Biomacromolecules · 2020Article
- Article
- Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.The AAPS journal · 2020Review
- Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity againstRSC advances · 2018Article
- Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.Bioconjugate chemistry · 2017Article
- Glycosylation of Recombinant Antigenic Proteins from Mycobacterium tuberculosis: In Silico Prediction of Protein Epitopes and Ex Vivo Biological Evaluation of New Semi-Synthetic Glycoconjugates.Molecules (Basel, Switzerland) · 2017Article
- Parasite Carbohydrate Vaccines.Frontiers in cellular and infection microbiology · 2017Review
- Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses.Vaccines · 2016Review
- Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation.Biomacromolecules · 2014Article
- Molecular factors in dendritic cell responses to adsorbed glycoconjugates.Biomaterials · 2014Article
- Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.Journal of biomaterials science. Polymer edition · 2014Article
- Glycan-mediated modification of the immune response.Oncoimmunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
The unique therapeutic value of dendritic cells (DCs) for the treatment of allergy, autoimmunity and transplant rejection is predicated upon our ability to selectively deliver antigens, drugs or nucleic acids to DCs in vivo. Here we describe a method for delivering whole protein antigens to DCs based on carbohydrate-mediated targeting of DC-expressed lectins. A series of synthetic carbohydrates was chemically-coupled to a model antigen, ovalbumin (OVA), and each conjugate was evaluated for its ability to increase the efficiency of antigen presentation by murine DCs to OVA-specific T cells (CD4(+) and CD8(+)). In vitro data are presented that demonstrate that carbohydrate modification of OVA leads to a 50-fold enhancement of presentation of antigenic peptide to CD4(+) T cells. A tenfold enhancement is observed for CD8(+) T cells; this indicates that the targeted lectin(s) can mediate cross-presentation of antigens on MHC class I. Our data indicate that the observed enhancements in antigen presentation are unique to OVA that is conjugated to complex oligosaccharides, such as a high-mannose nonasaccharide, but not to monosaccharides. Taken together, our data suggest that a DC targeting strategy that is based upon carbohydrate-lectin interactions is a promising approach for enhancing antigen presentation via class I and class II molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.